Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim that Letairis has embryo-fetal toxicity/major birth defects risk in pregnancy and is contraindicated during pregnancy is directly supported by the FDA label (Contraindications 4.1, Warnings/Precautions 5.1, Use in Specific Populations 8.1, and the Boxed Warning).
Category Scores
Accurate Statements
Embryo-fetal toxicity/major birth defects risk in pregnancy (Letairis may cause major birth defects and is contraindicated during pregnancy).
Supported by Contraindications 4.1 (contraindicated in pregnant females; may cause fetal harm; animal teratogenicity), Warnings/Precautions 5.1 (may cause fetal harm during pregnancy; contraindicated), Use in Specific Populations 8.1 (may cause fetal harm including birth defects and fetal death; contraindicated), and Boxed Warning (contraindicated during pregnancy due to potential major birth defects based on animal studies).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim matches the label’s contraindication and boxed warning regarding embryo-fetal toxicity; no conflicting or unsupported safety statement was made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement